2024-03-28T21:08:52Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_E123EA0B584E
2024-03-23T03:06:33Z
serval:BIB_E123EA0B584E
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
10.1016/j.annonc.2021.04.010
000761582600001
Soo
R.
author
Han
J-Y.
author
Dimopoulou
G.
author
Cho
B.C.
author
Yeo
C.M.
author
Nadal
E.
author
Carcereny
E.
author
de Castro
J.
author
Sala
M.A.
author
Bernabe
R.
author
Coate
L.
author
Provencio
M.
author
Campelo
R. Garcia
author
Cuffe
S.
author
Hashemi
S.
author
Früh
M.
author
Ruepp
B.
author
Roschitzki-Voser
H.
author
Stahel
R.
author
Peters
S.
author
article
editorial
2021-07
Annals of Oncology
0923-7534
journal
32
7
942-944
Oncology
Hematology
eng
60_published
true